Company research
ORAMED PHARMACEUTICALS INC.
CIK 1176309Updated Sep 27, 2026
SecurityORMP · NASDAQ · equity
Name history
Integrated Security Technologies, Inc. · through Apr 10, 2006IGUANA VENTURES LTD · through Jun 10, 2004
ORMP price & chart
Loading TradingView…
NASDAQ:ORMP on TradingView ↗About the company
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. Oramed’s Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed is building a diversified active investment portfolio while advancing its refined oral insulin program.
In the news
Oramed Reports Fiscal Third Quarter 2025 Financial Results News provided by Oramed Pharmaceuticals Inc. Nov 17, 2025, 08:56 ET Share this article Share to X Share this article Share to X Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Milli ↗
Recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
SCHEDULE 13G/A filing
10-Q filing
ARS filing
DEFA14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 230,864,000Source | 155,278,000Source | 220,551,000Source | 161,642,000Source |
| Property, Plant and Equipment, NetUSD | 586,000Source | 698,000Source | 873,000Source | 815,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 45,947,000Source | — | 9,055,000Source | — |
| Assets, CurrentUSD | 133,271,000Source | 143,221,000Source | 162,584,000Source | 157,109,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,741,000Source | 1,291,000Source | 537,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 750,000Source | 414,000Source | 694,000Source | 987,000Source |
| Other Assets, NoncurrentUSD | 44,000Source | 32,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 472,000Source | 480,000Source | 485,000Source | 476,000Source |
| Additional Paid in CapitalUSD | — | — | — | 314,417,000Source |
| Retained Earnings (Accumulated Deficit)USD | -123,436,000Source | -176,616,000Source | -157,556,000Source | -163,081,000Source |
| Stockholders' Equity Attributable to ParentUSD | 199,744,000Source | 146,265,000Source | 163,821,000Source | 151,812,000Source |
| Additional Paid in Capital, Common StockUSD | 322,708,000Source | 322,401,000Source | 320,892,000Source | — |
| Liabilities and EquityUSD | 230,864,000Source | 155,278,000Source | 220,551,000Source | 161,642,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,086,000Source | 5,685,000Source | 53,214,000Source | 5,746,000Source |
| Operating Lease, Liability, CurrentUSD | 285,000Source | 216,000Source | 267,000Source | 247,000Source |
| Accounts Payable, CurrentUSD | 443,000Source | 789,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 540,000Source | 156,000Source | 342,000Source | 647,000Source |
| Deferred Income Tax Liabilities, NetUSD | 7,911,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | — | 60,000Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | -918,000Source | -928,000Source | -656,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,084,000Source | 740,000Source | — | — |
| Deferred Revenue, CurrentUSD | — | — | — | 2,000,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 4,000,000Source | 4,000,000Source |
| Deferred Tax Liabilities, NetUSD | 7,911,000Source | — | — | — |
| Dividends Payable, CurrentUSD | 10,595,000Source | — | — | — |
| Dividends PayableUSD | 275,000Source | — | — | — |
| Long-term DebtUSD | — | — | — | 25,000Source |
| Short-term InvestmentsUSD | — | — | 57,713,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 64,016,000Source | -19,060,000Source | 5,088,000Source | -37,764,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,992,000Source | 4,053,000Source | 4,212,000Source | 11,509,000Source |
| Deferred Income Tax Expense (Benefit)USD | 7,911,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,145,000Source | -8,412,000Source | -10,295,000Source | -27,918,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 5,443,000Source | 105,817,000Source | -73,038,000Source | 30,211,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,000Source | 18,000Source | 254,000Source | 496,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 2,000Source | — | 783,000Source |
| Payments for Repurchase of Common StockUSD | 4,741,000Source | 2,484,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -4,741,000Source | -52,036,000Source | 51,978,000Source | 10,779,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -8,473,000Source | 45,365,000Source | -31,409,000Source | 13,008,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 45,947,000Source | 54,420,000Source | 9,055,000Source | 40,464,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 2,316,000Source | 574,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | 1,844,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -30,000Source | -4,000Source | -54,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,152,000Source | 4,053,000Source | — | — |
| DepreciationUSD | 121,000Source | 193,000Source | 196,000Source | 58,000Source |
| Dividends Payable, CurrentUSD | 10,595,000Source | — | — | — |
| Dividends PayableUSD | 275,000Source | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 1,637,000Source | -7,784,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -252,000Source | 174,000Source | 2,172,000Source | 1,550,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | 13,000Source |
| General and Administrative ExpenseUSD | 8,720,000Source | 6,457,000Source | 8,425,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 100,000Source |
| Income Tax Expense (Benefit)USD | 11,308,000Source | 3,183,000Source | — | 100,000Source |
| InterestExpenseNonoperatingUSD | — | 853,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 64,050,000Source | -19,103,000Source | 5,525,000Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -34,000Source | 43,000Source | -437,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 63,242,000Source | — | — | -36,561,000Source |
| Nonoperating Income (Expense)USD | 89,454,000Source | -2,286,000Source | 22,894,000Source | — |
| Other Nonoperating Income (Expense)USD | -606,000Source | 4,359Source | — | — |
| Payments to Acquire InvestmentsUSD | — | 1,307,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 2,428,000Source | 10,617,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,000,000Source | — | 1,340,000Source | 2,703,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -15,088,000Source | -12,781,000Source | -15,769,000Source | -40,598,000Source |
| Other Nonoperating Income (Expense)USD | -606,000Source | 4,359Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 75,324,000Source | -15,920,000Source | 5,088,000Source | — |
| Income Tax Expense (Benefit)USD | 11,308,000Source | 3,183,000Source | — | 100,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -34,000Source | 43,000Source | -437,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | 64,050,000Source | -19,103,000Source | 5,525,000Source | — |
| Earnings Per Share, BasicUSD per share | 1.53Source | -0.48Source | 0.14Source | 0.94Source |
| Earnings Per Share, DilutedUSD per share | 1.5Source | -0.48Source | 0.14Source | 0.94Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 41,402,997Source | 40,828,380Source | 40,315,068Source | 38,997,649Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 42,418,644Source | 40,828,380Source | 40,566,901Source | 38,997,649Source |
| Interest Expense (non-operating)USD | — | 853,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 3,573,000Source | — | — | 100,000Source |
| Debt Securities, Gain (Loss)USD | — | — | — | 43,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 1,637,000Source | -7,784,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -252,000Source | 174,000Source | 2,172,000Source | 1,550,000Source |
| General and Administrative ExpenseUSD | 8,720,000Source | 6,457,000Source | 8,425,000Source | — |
| Gross ProfitUSD | 13,000Source | — | — | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | -37,664,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | -8,853,000Source | 11,604,000Source | 11,164,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 100,000Source |
| Interest ExpenseUSD | — | — | 2,037,000Source | — |
| Interest Expense, DebtUSD | — | 2,587,000Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | 4,128,000Source | 8,016,000Source | 3,473,000Source |
| Interest Income, OtherUSD | 2,373,000Source | — | 10,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 63,242,000Source | — | — | -36,561,000Source |
| Nonoperating Income (Expense)USD | 89,454,000Source | -2,286,000Source | 22,894,000Source | — |
| Other ExpensesUSD | 238,000Source | 265,000Source | 236,000Source | 264,000Source |
| Other General ExpenseUSD | — | — | — | 1,040,000Source |
| Other IncomeUSD | 958,000Source | 67,000Source | 143,000Source | 100,000Source |
| Research and Development ExpenseUSD | 6,381,000Source | 6,324,000Source | 8,971,000Source | 27,639,000Source |
Filing attachments
ea027288901ex4-1_oramed.htm · 8-K · 2026-01-14
EX-4.1 2 ea027288901ex4-1_oramed.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDE…
Read attachment ↗ea027288901ex4-2_oramed.htm · 8-K · 2026-01-14
EX-4.2 3 ea027288901ex4-2_oramed.htm FORM OF SHARE PURCHASE WARRANT Exhibit 4.2 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT …
Read attachment ↗ea027288901ex4-3_oramed.htm · 8-K · 2026-01-14
EX-4.3 4 ea027288901ex4-3_oramed.htm FORM OF SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.3 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS N…
Read attachment ↗ea027288901ex4-4_oramed.htm · 8-K · 2026-01-14
EX-4.4 5 ea027288901ex4-4_oramed.htm FORM OF PURCHASE AGREEMENT WARRANT Exhibit 4.4 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM…
Read attachment ↗ea027288901ex99-1_oramed.htm · 8-K · 2026-01-14
EX-99.1 10 ea027288901ex99-1_oramed.htm PRESS RELEASE DATED JANUARY 13, 2026 Exhibit 99.1 FOR IMMEDIATE RELEASE January 13, 2026 Oramed and Lifeward Announce Strategic Transaction Transaction Will Transfer Oramed’s Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, …
Read attachment ↗ea027192901ex99-1_oramed.htm · 8-K · 2026-01-07
EX-99.1 2 ea027192901ex99-1_oramed.htm PRESS RELEASE DATED JANUARY 7, 2026 Exhibit 99.1 Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, January 7, 2026 - Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) today announced it has received a $18 mil…
Read attachment ↗